FRANKLIN LAKES, N.J., Sept. 7, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the sale of its Advanced Bioprocessing business to Thermo Fisher Scientific: “The sale of our Advanced Bioprocessing business will create greater focus for our Life Sciences segment where BD... Read more
FRANKLIN LAKES, N.J., Aug. 16, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Jeffrey W. Henderson has been elected to the company’s board of directors. Henderson, 53, is the non-executive chairman of the board of Qualcomm, Inc. and serves on the board of directors at FibroGen, Inc. and Halozyme Therapeutics, Inc. as well as serving... Read more
FRANKLIN LAKES, N.J., Aug. 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed Simon Campion as executive vice president of BD and president, BD Interventional segment, effective Sept. 4. Campion, 47, will report to Tom Polen, president of BD, and will be responsible for the... Read more
FRANKLIN LAKES, N.J., July 26, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of the BD® AbSeq assay to analyze protein expression at the single-cell level using high-throughput sequencing. The assay brings together high-quality antibodies from the BD Pharmingen™ portfolio with oligonucleotides,... Read more
FRANKLIN LAKES, N.J., July 12, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2017 Sustainability Performance Update that focuses on four key strategic areas that support the company’s 2020 Sustainability Goals. BD’s sustainability strategy is driven by its purpose – advancing the world of health... Read more
FRANKLIN LAKES, N.J., July 9, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of TVA Medical, Inc., a company that develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring hemodialysis. In the U.S. alone, there are... Read more
DENVER, June 4, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Helmer Scientific, a leading provider of integrated solutions to safeguard temperature-sensitive medications, today announced a collaboration to introduce an industry-first, medical-grade refrigerated solution integrated with an automated dispensing system to provide clinicians secure, single line-item access... Read more
FRANKLIN LAKES, N.J., June 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Jefferies 2018 Global Healthcare ConferenceJune 8, 201810:00 a.m. EDT Goldman Sachs 38th Annual Global Healthcare ConferenceJune 13, 20188:40 a.m. EDT Live webcasts... Read more
FRANKLIN LAKES, N.J., June 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer. DeFord, 56, will report to Tom Polen, president of BD, and will be responsible for leading all research and development (R&D) activities... Read more
FRANKLIN LAKES, N.J., April 27, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced three executive appointments to the positions of segment president. Alberto Mas, 56, has been named president of the Medical Segment for BD, effective May 29, reporting to Tom Polen, president of BD.... Read more